BDBM637629 BDBM637651::US20230382923, Compound 24::US20230382923, Compound 48

SMILES CN(C)C\C=C\C(=O)N1CCN2C[C@@H]1COc1cc3ncnc(Nc4cc(C)c(Oc5ccn6ncnc6c5)cc4F)c3nc21

InChI Key InChIKey=SDAXRPZVCMFHRU-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 637629   

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM637629(US20230382923, Compound 24 | US20230382923, Compou...)
Affinity DataIC50: 6.84nMAssay Description:Table B3: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated ERBB2 levels. A capture antibody able to detect phospho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM637629(US20230382923, Compound 24 | US20230382923, Compou...)
Affinity DataIC50: 8.38nMAssay Description:Table B3: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated ERBB2 levels. A capture antibody able to detect phospho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM637629(US20230382923, Compound 24 | US20230382923, Compou...)
Affinity DataIC50: 10.8nMAssay Description:Table B3: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated ERBB2 levels. A capture antibody able to detect phospho...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM637629(US20230382923, Compound 24 | US20230382923, Compou...)
Affinity DataIC50: 2.16E+3nMAssay Description:Table B4: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated EGFR levels using A431 cells (10% FBS). A431 (1.0*104ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM637629(US20230382923, Compound 24 | US20230382923, Compou...)
Affinity DataIC50: 2.47E+3nMAssay Description:Table B4: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated EGFR levels using A431 cells (10% FBS). A431 (1.0*104ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Enliven Therapeutics

US Patent
LigandPNGBDBM637629(US20230382923, Compound 24 | US20230382923, Compou...)
Affinity DataIC50: 3.30E+3nMAssay Description:Table B4: Enzyme-linked immunosorbent assays (ELISA) were performed to measure phosphorylated EGFR levels using A431 cells (10% FBS). A431 (1.0*104ce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent